2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1222

Impact of Bariatric Surgery on Bone Mineral Density : Observational Study of 110 Patients Followed up in a Specialised Centre for the Treatment of Obesity in France
Abstract Number: 1453

Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts
Abstract Number: 2377

Impact of Body Mass Index and Weight Loss on Incident Disability in Patients with Rheumatoid Arthritis
Abstract Number: 1162

Impact of Bone Localization on the Prognostic of Langerhans Cell Histiocytosis: A Monocentric Retrospective Study
Abstract Number: 528

Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Abstract Number: 743

Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort
Abstract Number: 1129

Impact of Diuretics on Urate Lowering Therapy in Patients with Gout: Analysis of an Inception Cohort
Abstract Number: 989

Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Abstract Number: 1344

Impact of Fibromyalgic RA on Composite Scores; Results from a Longitudinal Study of RA Patients Initiating Bdmard Therapy
Abstract Number: 1424

Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Abstract Number: 2512

Impact of Inflammatory Bowel Disease in Early Spondyloarthritis in a Prospective Longitudinal Cohort
Abstract Number: 1957

Impact of Maternal Systemic Autoimmune Rheumatic Diseases on Neonatal Outcomes: A Population-Level Analysis
Abstract Number: 2246

Impact of Patient Education Tool to Increase Cardiovascular Risk Konwledge, Attitudes, and Behaviors in Patietns with Rheumatoid Arthritis
Abstract Number: 1038

Impact of Patient Support Program Utilization on Patient Activation Measure Scores Among Patients with Rheumatoid Arthritis
Abstract Number: 2677

Impact of Rheumatologic Evaluation and Serologic Testing on Patients with Fibrotic Interstitial Lung Disease: A Single Center Retrospective Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].